# Osmotin-derived 9-amino-acid peptide alleviates α-synuclein and MPTP-induced glial cell activation mediated neuroinflammation, protecting dopaminergic neurons in Parkinson’s disease mice brain

## TL;DR

A new 9-amino-acid peptide from osmotin protects brain cells in Parkinson’s disease models by reducing inflammation and preserving dopamine neurons.

## Contribution

The novel Os_9aa peptide is shown to reduce neuroinflammation and protect dopaminergic neurons in multiple Parkinson’s disease models.

## Key findings

- Os_9aa reduced glial cell activation and pro-inflammatory cytokines in PD mouse models.
- The peptide preserved key dopaminergic markers like tyrosine hydroxylase and dopamine transporter.
- Os_9aa improved cognitive performance and mitigated oxidative stress in Parkinson’s disease models.

## Abstract

Parkinson’s disease (PD) is the second most common neurodegenerative disorder, categorized by the loss of dopaminergic neurons in the brain’s Substantia Nigra pars compacta (SNpc) due to α-synuclein (α-syn) aggregation, leading to reduced dopamine levels in the striatum. This research study evaluates the neuroprotective potential of the novel peptide osmotin-derived 9-amino-acid (Os_9aa, C-T-Q-G-P-C-G-P-T) against α-syn (neuron-specific enolase promoter human alpha-synuclein (NSE-hαSyn)) and 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced PD models.

Human neuroblastoma SH-SY5Y cells were employed as an in vitro model, while NSE-hαSyn (α-synuclein) transgenic mice and MPTP-treated mice were used as in vivo models of PD. MPTP was administered intraperitoneally (30 mg/kg) once daily for five consecutive days. Mice were immunized with Os_9aa (15 mg/kg, i.p., twice weekly for five weeks), followed by behavioral assessments including open field test, wire hang test, pole test, and rotarod test, and biochemical analysis using the Triplex Assay, western blotting, and confocal microscopy.

Our study demonstrated that the novel peptide Os_9aa enhanced cell viability, reduced cytotoxicity, and apoptosis in SH-SY5Y neuroblastoma cells. Os_9aa attenuated synucleinopathy-related pathology in NSE-hαSyn transgenic mice and MPTP-induced PD mouse models. Current findings also highlighted the therapeutic potential of Os_9aa in mitigating behavioral deficits observed in NSE-hαSyn and MPTP mouse models of PD. Furthermore, Os_9aa administration effectively restored key dopaminergic markers, including tyrosine hydroxylase (TH), vesicular monoamine transporter 2 (VMAT2), and dopamine transporter (DAT). Additionally, it reduced neuroinflammation by decreasing the activation of glial cells—ionized calcium-binding adaptor molecule 1 (Iba-1) and glial fibrillary acidic protein (GFAP), as well as pro-inflammatory cytokines, such as phosphorylated nuclear factor-κB (p-NF-кB), tumor necrosis factor-α (TNF-α), and interleukin-1β (IL-1β), in the striatum and SNpc regions. Furthermore, Os_9aa mitigated oxidative stress (OS) by upregulating the expression of nuclear factor erythroid-related factor 2 (Nrf-2) and heme oxygenase 1 (HO-1), and improved cognitive performance.

Collectively, these findings highlight the neuroprotective potential of the Os_9aa, which counteracts α-synuclein– and MPTP-induced neurotoxicity by reducing oxidative stress, glial activation, and neuroinflammation. This multifaceted protection preserves neuronal integrity in both the NSE-hαSyn transgenic and MPTP-induced PD mouse models, underscoring Os_9aa as a promising therapeutic candidate for modifying PD pathogenesis.